Hummingbird Bioscience

On 9th October 2024, Hummingbird Bioscience supported Pathlight School in facilitating the school’s visit to the National Gallery. As part of the school’s holistic education, students had the opportunity to view art exhibitions by Teo Eng Seng and Kim Lim, and explore Keppel Centre for Art Education. Hummingbird Bio had a great time with the students and we hope the experience was enriching for the students! 

Press release: https://bit.ly/3A9GSL3 Hummingbird Bioscience will present a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium. Poster details: Title: A novel HER2 targeted dual-payload ADC, HMBD-802, overcomes resistance to topoisomerase 1 inhibitor ADCs Date: 24 October 2024 Location: Exhibition Hall Session: Antibody-drug conjugates Poster number: PB154 Abstract number: 166   #antibodydrugconjugates #ENA2024

Angele Maki, Chief Business Officer of Hummingbird Bioscience, will be attending BIO-Europe in Stockholm, Sweden from 4-5 November. To learn more about our validated epitope-focused antibody discovery platform capabilities, please reach out to connect with Angèle. #antibodydiscovery

Ben Ayers, VP of Antibody-Drug Conjugates at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering & Therapeutics Asia.   Our dual-payload ADC technologies present a single-agent approach with the potential to provide significant patient benefit and overcome challenges of earlier generation ADCs, systemically-administered chemotherapies and their combinations. If you will be at Antibody Engineering & Therapeutics Asia, attend the talk to learn more.   #adc #drugresistance #biotech

Jerome Boyd-Kirkup, Chief Scientific Officer of Hummingbird Bioscience will be presenting how our epitope-focused antibody discovery technologies can unlock a broad range of next-generation antibody-based modalities at the Festival of Biologics (15-17 October 2024) in Basel, Switzerland. We look forward to showcasing our proprietary antibody discovery capabilities which include AI algorithms and transgenic mice with both a poster presentation and keynote speech. If you are interested to learn more about our platform, please connect with us.   #festivalofbiologics #biologics #antibodydiscovery 

Angele Maki, Chief Business Officer of Hummingbird Bioscience, will be in Cambridge next week on October 9th and 10th to attend the Oncology Venture, Innovation & Partnering Summit.   We hope you will reach out to connect and learn more about our AI-powered antibody discovery platform and our clinical-stage assets.   #oncology #partnering #biotech

For the second year running, the Hummingbird Bioscience team laced up our shoes and joined the Race Against Cancer yesterday!   Organized by Singapore Cancer Society and Singtel, the 2024 Race Against Cancer raises funds to assist the cancer community through well-rounded financial and welfare services.   Hummingbird Bioscience is delighted to contribute to this meaningful cause and the community.   #RAC2024 #RaceAgainstCancer24 #SCS #SCS60 #aracetosavelives 

Scientific research plays a pivotal role in the fight against cancer. This year, World Cancer Research Day focuses on innovation under the motto ‘Innovation In Cancer Research Drives Progress Toward Health Equity’. The theme highlights how crucial innovative research is in closing the gap in cancer care. At Hummingbird Bioscience, we aim to improve outcomes for cancer patients worldwide with our work in researching and developing innovative therapies. Our strong research capabilities are possible only with our united team, who have worked tirelessly to bring our therapies to patients. Meet some of our team! Learn more about #WorldCancerResearchDay: https://bit.ly/4gI2LBM

Scientific research plays a pivotal role in the fight against cancer. This year, World Cancer Research Day focuses on innovation under the motto ‘Innovation In Cancer Research Drives Progress Toward Health Equity’. The theme highlights how crucial innovative research is in closing the gap in cancer care. At Hummingbird Bioscience, we aim to improve outcomes for cancer patients worldwide with our work in researching and developing innovative therapies. Our strong research capabilities are possible only with our united team, who have worked tirelessly to bring our therapies to patients. Meet some of our team! Learn more about #WorldCancerResearchDay: https://bit.ly/4gI2LBM

Angele Maki, Chief Business Officer of Hummingbird Bioscience, will be attending the upcoming Oppenheimer & Co. Inc. Houston Oncology Summit organized in collaboration with MD Anderson Cancer Center on Thursday, September 26th.  Catch up with Angèle to learn more about our AI-powered antibody discovery platform and our clinical-stage assets.   #biotech #ThePowerofOppenheimerThinking